Skip to main content

Peer Review reports

From: Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

Original Submission
18 Jan 2022 Submitted Original manuscript
22 Jan 2022 Author responded Author comments - Yiping Zhang
Resubmission - Version 2
22 Jan 2022 Submitted Manuscript version 2
29 Jan 2022 Author responded Author comments - Yiping Zhang
Resubmission - Version 3
29 Jan 2022 Submitted Manuscript version 3
14 Feb 2022 Reviewed Reviewer Report
17 Feb 2022 Reviewed Reviewer Report
17 Feb 2022 Reviewed Reviewer Report
20 Mar 2022 Author responded Author comments - Zhengbo Song
Resubmission - Version 4
20 Mar 2022 Submitted Manuscript version 4
22 Mar 2022 Reviewed Reviewer Report
28 Mar 2022 Author responded Author comments - Zhengbo Song
Resubmission - Version 5
28 Mar 2022 Submitted Manuscript version 5
Publishing
29 Mar 2022 Editorially accepted
10 May 2022 Article published 10.1186/s12916-022-02361-w

You can find further information about peer review here.

Back to article page